Cambridge, UK, 02 November 2021: Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor. He joins senior biopharma industry executives, Dr. Jane Osbourn OBE (Chair) and Dr. Lorenz Mayr, as an independent member of the Board of Directors. Tom is a seasoned financial executive bringing a wealth of global experience that spans corporate…
Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr Peter Jackson, executive director, Infex Therapeutics, said:
“The announcement today that the government is increasing public R&D investment to record levels to cement the UK as a global science and technology superpower is hugely encouraging news, and reflects the importance of innovative, entrepreneurial companies to the future economic wellbeing of our country as we seek to recover from the pandemic.
“In particular it is very encouraging to see funding for Innovate UK increasing significantly to £1.1 billion by…
"Diagnostics - More important than ever, but there's still a way to go".
Diagnostics are clearly improving and enabling better clinical decisions to be made, especially in oncology where mutation detection is enabling much more personalised approaches to treatment. There is still a long way to go, but combinations of diagnostics tests and technologies (beyond genomics) are giving a more detailed picture on which to base treatment decisions.
Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company itformed in 2016 and…
Oxford, UK, Friday 15th October: PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio. This follows the recent announcement that IntoCell has established a research collaboration partnership with Ab Studio to develop antibody drug conjugate (ADC) using IntoCell’s proprietary PMT payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker technology, and a novel internalizing antibody from Ab Studio. Steve Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted IntoCell…
AMSBIO report that researchers from the Medical University of Vienna (Austria), have used Lipidure® - CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.
The aim of the research by the Medical University of Vienna was to create physiological-relevant in vitro tissue models that offer better predictability and the potential to improve drug screening outcomes in pre-clinical studies. Despite the advances of spheroid models in pharmaceutical screening applications, variations in spheroid size and consequential altered cell responses traditionally have led to…
London, UK, 27 October 2021 – Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited (“Takeda”) for a pre-negotiated upfront payment, as well as potential development and regulatory milestones. GammaDelta Therapeutics is a UK-headquartered company founded upon world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute and supported by Cancer Research Technology. GammaDelta is focused on…
Dr Marcin Mankowski, Co-founder and Deputy Managing Partner of tranScrip, has been appointed tranScrip’s new Managing Partner.
Marcin has been integral to the success of the business over the last decade and is transitioning to the role at an exciting stage of the company’s growth. Underpinned by a recent significant minority investment from Palatine Private Equity Impact Fund, tranScrip is set to rapidly drive revenues with both organic growth and strategic acquisitions.
Marcin is a highly respected pharmaceutical physician with more than 25 years of big pharma, biotech and service sector…
22nd October 2021 (Rotterdam/Cambridge) – F.INSTITUTE, a Dutch full service finance company for the life sciences, pharma, biotech, deep tech and new energy sector, has recently expanded its portfolio of book-keeping, tax, and CFO services into the UK market. With the appointment of Charles Richmond as their new Director Accounting UK, the company takes the next step towards becoming a dominant player within the international market. In this new position, Charles Richmond is responsible for continued growth of the overall high-quality portfolio. His mission includes giving further…
Click here to view the October 2021 edition of Dates for Your Diary
TOKYO and NOTTINGHAM, UK |21 October 2021 - Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc, and We are Pioneer Group (WAPG), the UK’s largest ecosystem provider for science and innovation businesses, today announce a new collaborative sponsorship and first of its kind initiative to support early stage science ventures. The “Future Innovator Prize” offers scientists and biotech start-ups one year of free accommodation at selected We are Pioneer Group locations and membership to the WAPG’s community of scientists, technologists and…